• Home
  • R&D


OliX Pipeline

  • Pipeline
  • OLX101A
  • OLX104C
  • OLX301A
  • OLX301D
  • OLX702A
  • OLX703A


Hepatitis B Treatment

OLX703A targets a sequence that is common to all viral transcripts of hepatitis B virus (HBV),
with the aim of reducing serum levels of HBV surface antigen.
It also has the advantage of targeting sequences that are conserved in over 90% of 10 genotypes,
making the drug applicable to a diverse range of patients, including those resistant to existing antiviral drugs.

Target RNA: HBV transcripts

Administration Route: Subcutaneous Injection

Hepatitis B

Hepatitis B, a type of viral hepatitis, is transmitted through blood or body fluids. When a cell is infected, it triggers an immune response to eliminate the virus, often causing liver inflammation. The process can lead to cirrhosis and, ultimately, liver cancer. The viral genome is stored in infected liver cells as cccDNA (covalently closed circular DNA), in which the disease can persist chronically even after antiviral treatment.

Preclinical Data

Development Status

  • Efficacy verified in AAV-HBV mouse model
  • Long-term (over 4 weeks) efficacy with a single dose verified

Conference Presentation

  • 2021 RNAi-Based Therapeutics Summit (21.06)
  • 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
  • 2022 Smi RNA Therapeutics Conference (22.02)
  • 2022 OPT (Oligonucleotide & Precision Therapeutics) Congress (22.03)